Dohj LLC Boosts Stake in Amgen Inc. (NASDAQ:AMGN)

Dohj LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,727 shares of the medical research company’s stock after buying an additional 72 shares during the quarter. Dohj LLC’s holdings in Amgen were worth $1,161,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital World Investors lifted its position in Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the period. Norges Bank purchased a new position in Amgen during the fourth quarter worth about $1,541,991,000. GAMMA Investing LLC lifted its position in Amgen by 43,573.5% during the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after buying an additional 3,653,205 shares during the period. Capital International Investors lifted its position in Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after buying an additional 2,672,975 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.76% of the company’s stock.

Amgen Stock Performance

Shares of Amgen stock opened at $295.22 on Friday. The firm has a market cap of $158.74 billion, a price-to-earnings ratio of 39.10, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The stock’s 50-day moving average is $281.33 and its 200-day moving average is $285.62. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the prior year, the company posted $3.96 earnings per share. Amgen’s revenue was up 9.4% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent analyst reports. UBS Group reiterated a “neutral” rating and set a $315.00 target price (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on Amgen in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 target price on the stock. Johnson Rice set a $294.00 price objective on Amgen in a report on Wednesday, March 5th. Morgan Stanley restated an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Finally, Erste Group Bank downgraded Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.